Overview
- discovery and validation of biomarker predicting gastric cancer chemotherapy response
- Analysis for expression level of mRNA using Next generation sequencing in gastric cancer tissue by chemotherapy response
- Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response
- Validation of mRNA and miRNA using qRT-PCR in multiple independent cohort
- Biological biomarkers-clinical factor combined prediction model of gastric cancer chemotherapy response
Description
- discovery and validation of biomarker predicting gastric cancer chemotherapy response
- Analysis for expression level of mRNA in fresh frozen gastric cancer tissue by chemotherapy response (A) method of mRNA expression measurement: RNA sequencing (B) study group Palliative chemotherapy (inoperable patients)
- institutional primary Chemotherapy regimen (XP or Xelox)
- response group
- progression group
Post-OP adjuvant chemotherapy
- institutional primary Chemotherapy regimen
- complete response group
- non-responder group
- and 2) groups: age, sex, regimen matched
- Analysis for expression level of miRNA using Next generation sequencing in gastric cancer tissue and blood by chemotherapy response (A) method of mRNA expression measurement: RNA sequencing (B) study group
- the same patients in mRNA sequencing
- Validation of mRNA and miRNA in multiple independent cohort method of measurement of RNA expression: qRT-PCR
- Biological biomarkers-clinical factor combined prediction model of gastric cancer chemotherapy response combination of biologic biomarker and clinical factors to predict the chemotherapy response in gastric cancer
Eligibility
Inclusion Criteria:
- new gastric cancer patients who has scheduled to start 1st cycle of chemotherapy
- patients who agreed this study and voluntarily assigned the informed consents.
Exclusion Criteria:
- patients who refused the study.
- patients who have other cancers
- heavy alcoholics